Literature DB >> 29250170

Liver X receptors as potential targets for cancer therapeutics.

Xiaoli Ju1, Pan Huang1, Miao Chen1,2, Qiang Wang3.   

Abstract

Liver X receptors (LXRs) are important members of the nuclear receptor family that were originally determined to function in cholesterol transport and the regulation of immune responses. Synthetic LXR ligands have been developed to treat various diseases including diabetes, Alzheimer's disease and atherosclerosis. Previous studies have suggested that LXRs are also involved in numerous types of cancer and are therefore potential targets for cancer therapeutics. The present review summarizes LXR ligands and their mechanisms of action, the effects of LXRs in different types of cancer and their potential applications in clinical treatment. Together, the studies discussed in the present review indicate that LXRs may be potential targets for cancer therapeutics.

Entities:  

Keywords:  cancer; cancer therapeutics; clinical application; liver X receptors

Year:  2017        PMID： 29250170      PMCID： PMC5727639          DOI： 10.3892/ol.2017.7259

Source DB:  PubMed          Journal:  Oncol Lett        ISSN： 1792-1074            Impact factor:   2.967


  52 in total

1.  A unified nomenclature system for the nuclear receptor superfamily.

Authors: 
Journal:  Cell       Date:  1999-04-16       Impact factor: 41.582

Review 2.  Principles for modulation of the nuclear receptor superfamily.

Authors:  Hinrich Gronemeyer; Jan-Ake Gustafsson; Vincent Laudet
Journal:  Nat Rev Drug Discov       Date:  2004-11       Impact factor: 84.694

3.  Inhibition of Pancreatic Cancer Cell-Induced Paracrine Hedgehog Signaling by Liver X Receptor Agonists and Oxy16, a Naturally Occurring Oxysterol.

Authors:  Feng Wang; Frank Stappenbeck; William Matsui; Farhad Parhami
Journal:  J Cell Biochem       Date:  2016-09-21       Impact factor: 4.429

4.  Cross-talk between the androgen receptor and the liver X receptor: implications for cholesterol homeostasis.

Authors:  James Robert Krycer; Andrew John Brown
Journal:  J Biol Chem       Date:  2011-04-13       Impact factor: 5.157

5.  Estrogen deprivation and inhibition of breast cancer growth in vivo through activation of the orphan nuclear receptor liver X receptor.

Authors:  Haibiao Gong; Ping Guo; Yonggong Zhai; Jie Zhou; Hirdesh Uppal; Michael J Jarzynka; Wen-Chao Song; Shi-Yuan Cheng; Wen Xie
Journal:  Mol Endocrinol       Date:  2007-05-29

6.  LXR agonists and ABCG1-dependent cholesterol efflux in MCF-7 breast cancer cells: relation to proliferation and apoptosis.

Authors:  Ali El Roz; Jean-Marie Bard; Jean-Michel Huvelin; Hassan Nazih
Journal:  Anticancer Res       Date:  2012-07       Impact factor: 2.480

7.  Suppression of beta-catenin signaling by liver X receptor ligands.

Authors:  Shigeyuki Uno; Kaori Endo; Yangsik Jeong; Katsuyoshi Kawana; Hiroyuki Miyachi; Yuichi Hashimoto; Makoto Makishima
Journal:  Biochem Pharmacol       Date:  2008-10-15       Impact factor: 5.858

8.  Broad-spectrum therapeutic suppression of metastatic melanoma through nuclear hormone receptor activation.

Authors:  Nora Pencheva; Colin G Buss; Jessica Posada; Taha Merghoub; Sohail F Tavazoie
Journal:  Cell       Date:  2014-02-27       Impact factor: 41.582

9.  Liver X receptor β activation induces pyroptosis of human and murine colon cancer cells.

Authors:  V Derangère; A Chevriaux; F Courtaut; M Bruchard; H Berger; F Chalmin; S Z Causse; E Limagne; F Végran; S Ladoire; B Simon; W Boireau; A Hichami; L Apetoh; G Mignot; F Ghiringhelli; C Rébé
Journal:  Cell Death Differ       Date:  2014-08-15       Impact factor: 15.828

10.  Apoptotic cells promote their own clearance and immune tolerance through activation of the nuclear receptor LXR.

Authors:  Noelia A-Gonzalez; Steven J Bensinger; Cynthia Hong; Susana Beceiro; Michelle N Bradley; Noam Zelcer; Jose Deniz; Cristina Ramirez; Mercedes Díaz; German Gallardo; Carlos Ruiz de Galarreta; Jon Salazar; Felix Lopez; Peter Edwards; John Parks; Miguel Andujar; Peter Tontonoz; Antonio Castrillo
Journal:  Immunity       Date:  2009-07-30       Impact factor: 31.745
View more
  6 in total

Review 1.  Immunotherapies targeting stimulatory pathways and beyond.

Authors:  Julian A Marin-Acevedo; ErinMarie O Kimbrough; Rami Manochakian; Yujie Zhao; Yanyan Lou
Journal:  J Hematol Oncol       Date:  2021-05-12       Impact factor: 17.388

2.  Modulation of LXR signaling altered the dynamic activity of human colon adenocarcinoma cancer stem cells in vitro.

Authors:  Hassan Dianat-Moghadam; Mostafa Khalili; Mohsen Keshavarz; Mehdi Azizi; Hamed Hamishehkar; Reza Rahbarghazi; Mohammad Nouri
Journal:  Cancer Cell Int       Date:  2021-02-10       Impact factor: 5.722

3.  iTRAQ-Based Proteomic Analysis Reveals Potential Serum Biomarkers for Pediatric Non-Hodgkin's Lymphoma.

Authors:  Runhong Yu; Linna Cheng; Shiwei Yang; Yufeng Liu; Zunmin Zhu
Journal:  Front Oncol       Date:  2022-03-17       Impact factor: 6.244

Review 4.  Cancer therapy's impact on lipid metabolism: Mechanisms and future avenues.

Authors:  Roshni Bhatnagar; Neal M Dixit; Eric H Yang; Tamer Sallam
Journal:  Front Cardiovasc Med       Date:  2022-08-09

5.  The lipogenic LXR-SREBF1 signaling pathway controls cancer cell DNA repair and apoptosis and is a vulnerable point of malignant tumors for cancer therapy.

Authors:  Bo Yang; Bin Zhang; Zhifei Cao; Xingdong Xu; Zihe Huo; Pan Zhang; Shufen Xiang; Zhe Zhao; Chunping Lv; Mei Meng; Gaochuan Zhang; Liang Dong; Shucheng Shi; Lan Yang; Quansheng Zhou
Journal:  Cell Death Differ       Date:  2020-03-06       Impact factor: 15.828

6.  Liver X receptor activation reduces gastric cancer cell proliferation by suppressing Wnt signalling via LXRβ relocalization.

Authors:  Qiang Wang; Fan Feng; Jiayou Wang; Meijia Ren; Zhonggang Shi; Xiang Mao; Heng Zhang; Xiaoli Ju
Journal:  J Cell Mol Med       Date:  2018-10-19       Impact factor: 5.310
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.